ORBIMED ADVISORS LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001055951
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2026 · 119 positions · Total reported value $4.97B · Top-10 concentration 45.7% · Updated 2026-10-24
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
Turnover: 60.6% · 34 new · 29 cut · 23 exited
Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2026 13F filing, ORBIMED ADVISORS LLC disclosed 119 equity positions with a combined reported value of $4.97B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2026 were EWTX ($630.52M), ELVN ($343.91M), LLY ($309.33M). By sector, the heaviest allocations are Health Care 92.3%, Industrials 1.5%.
Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 60% of names.
The largest new positions opened in Q2 2026 were HUM ($65.18M), ODTX ($56.15M), ARQT ($53.54M).
Of the 23 positions fully exited versus the prior quarter, the largest were MDXH ($285.90M), MYGN ($122.88M), PFE ($54.66M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2026)
- HUM HUMANA INC COM · $65.18M
- ODTX ODYSSEY THERAPEUTICS INC · $56.15M
- ARQT ARCUTIS BIOTHERAPEUTICS INC COM · $53.54M
- XBI SPDR SERIES TRUST · $47.48M
- WST WEST PHARMACEUTICAL SVSC INC COM · $25.35M
- AURA AURA BIOSCIENCES INC · $23.67M
- SYRE SPYRE THERAPEUTICS INC COM NEW · $16.53M
- WAT WATERS CORP · $15.11M
Fully Exited (vs previous quarter)
- MDXH MDXHEALTH SA · prev qtr: $285.90M
- MYGN MYRIAD GENETICS INC COM · prev qtr: $122.88M
- PFE PFIZER INC · prev qtr: $54.66M
- DHR DANAHER CORP DEL · prev qtr: $50.40M
- RCEL AVITA MEDICAL INC · prev qtr: $42.52M
- ESPR ESPERION THERAPEUTICS INC NE · prev qtr: $28.96M
- BTSG BRIGHTSPRING HEALTH SVCS INC COM · prev qtr: $21.21M
- AMGN AMGEN INC · prev qtr: $14.04M
Insider Transactions (Form 4)
Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 2,000 | $8.45 | SEC filing |
| 2026-11-10 | Buy | Electra Therapeutics, Inc. | 20,700 | $8.45 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 16,000 | $8.24 | SEC filing |
| 2026-11-09 | Buy | Electra Therapeutics, Inc. | 4,000 | $8.24 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 39,600 | $7.85 | SEC filing |
| 2026-11-06 | Buy | Electra Therapeutics, Inc. | 9,816 | $7.85 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 125,200 | $7.31 | SEC filing |
| 2026-11-05 | Buy | Electra Therapeutics, Inc. | 30,891 | $7.31 | SEC filing |
Fund Profile
ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.
Investment Approach
ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.
Asset Classes
ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.
Key People
Samuel Isen - Co-founder and Managing Partner
Steven Bloom - Co-founder and Managing Partner
The firm also has several other managing partners and investment professionals
Notable Facts
ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.
This information is based on public disclosures; investment decisions should reference official filings.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
15.52M | $630.52M | 12.68% | Hold | |
| 2 |
|
6.78M | $343.91M | 6.91% | Reduce | |
| 3 |
|
257.90K | $309.33M | 6.22% | Add | |
| 4 |
|
3.43M | $189.27M | 3.81% | Reduce | |
| 5 |
|
2.72M | $184.47M | 3.71% | Hold | |
| 6 |
|
915.70K | $171.08M | 3.44% | Add | |
| 7 |
|
2.21M | $118.58M | 2.38% | Add | |
| 8 |
|
2.56M | $112.43M | 2.26% | Reduce | |
| 9 |
|
7.17M | $107.05M | 2.15% | Hold | |
| 10 |
|
3.03M | $105.17M | 2.11% | Hold | |
| 11 |
|
583.70K | $87.57M | 1.76% | Add | |
| 12 |
|
92.88K | $86.17M | 1.73% | Reduce | |
| 13 |
|
663.40K | $85.25M | 1.71% | Hold | |
| 14 |
|
1.81M | $83.25M | 1.67% | Reduce | |
| 15 |
|
230.10K | $77.04M | 1.55% | Add | |
| 16 |
|
834.90K | $75.53M | 1.52% | Reduce | |
| 17 |
|
3.24M | $71.86M | 1.45% | Add | |
| 18 |
|
262.00K | $71.12M | 1.43% | Hold | |
| 19 |
|
972.80K | $69.12M | 1.39% | Add | |
| 20 |
|
8.29M | $66.39M | 1.33% | Hold | |
| 21 |
|
244.46K | $65.20M | 1.31% | Add | |
| 22 |
|
164.10K | $65.18M | 1.31% | New | |
| 23 |
|
1.48M | $63.30M | 1.27% | Reduce | |
| 24 |
|
157.90K | $62.79M | 1.26% | Reduce | |
| 25 |
|
2.11M | $56.94M | 1.15% | Add | |
| 26 |
|
3.00M | $56.15M | 1.13% | New | |
| 27 |
|
892.47K | $53.87M | 1.08% | Reduce | |
| 28 |
|
2.04M | $53.54M | 1.08% | New | |
| 29 |
|
925.00K | $53.30M | 1.07% | Hold | |
| 30 |
|
4.13M | $52.59M | 1.06% | Add | |
| 31 |
|
159.10K | $50.09M | 1.01% | Reduce | |
| 32 |
|
2.81M | $50.02M | 1.00% | Hold | |
| 33 |
|
300.00K | $47.48M | 0.95% | New | |
| 34 |
|
90.70K | $45.47M | 0.91% | Add | |
| 35 |
|
6.31M | $43.76M | 0.88% | Hold | |
| 36 |
|
5.69M | $39.40M | 0.79% | Hold | |
| 37 |
|
999.00K | $37.38M | 0.75% | Hold | |
| 38 |
|
322.90K | $35.85M | 0.72% | Add | |
| 39 |
|
1.54M | $33.71M | 0.68% | Add | |
| 40 |
|
1.58M | $33.53M | 0.67% | Add | |
| 41 |
|
15.22M | $33.33M | 0.67% | Hold | |
| 42 |
|
465.35K | $32.49M | 0.65% | Add | |
| 43 |
|
83.20K | $30.92M | 0.62% | Add | |
| 44 |
|
5.68M | $30.28M | 0.61% | Reduce | |
| 45 |
|
117.58K | $28.78M | 0.58% | Reduce | |
| 46 |
|
420.60K | $26.90M | 0.54% | Add | |
| 47 |
|
1.43M | $26.67M | 0.54% | Reduce | |
| 48 |
|
200.00K | $26.65M | 0.54% | Reduce | |
| 49 |
|
357.54K | $26.15M | 0.53% | Reduce | |
| 50 |
|
70.60K | $25.35M | 0.51% | New | |
FAQ
What did ORBIMED ADVISORS LLC buy in 2026-Q2?
In its 2026-Q2 13F filing, ORBIMED ADVISORS LLC reported 119 equity positions worth $4.97B in aggregate; its largest disclosed positions were EWTX ($630.52M), ELVN ($343.91M), LLY ($309.33M).
How large is ORBIMED ADVISORS LLC's portfolio?
ORBIMED ADVISORS LLC reported $4.97B of long equity holdings across 119 positions as of 2026-Q2. Top-10 holdings account for 45.7% of reported value.
What is ORBIMED ADVISORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.